melagatran has been researched along with sulfasalazine in 2 studies
| Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (sulfasalazine) | Trials (sulfasalazine) | Recent Studies (post-2010) (sulfasalazine) |
|---|---|---|---|---|---|
| 185 | 32 | 19 | 4,437 | 585 | 938 |
| Protein | Taxonomy | melagatran (IC50) | sulfasalazine (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 1.5 | |
| Solute carrier organic anion transporter family member 2B1 | Homo sapiens (human) | 3 | |
| Carbonic anhydrase 1 | Homo sapiens (human) | 3.04 | |
| Carbonic anhydrase 2 | Homo sapiens (human) | 4.49 | |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | 6.332 | |
| Sodium/bile acid cotransporter | Homo sapiens (human) | 9.6 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 0.46 | |
| Cystine/glutamate transporter | Homo sapiens (human) | 0.16 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 0.56 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
2 other study(ies) available for melagatran and sulfasalazine
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |